Developing novel drugs that can abrogate the growth and metastasis of malignant tumors is a major challenge for cancer researchers. WYC-209, a synthetic retinoid, inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs). The enantiomers WYC-209A and WYC-209B exhibit similar TRC inhibition activities. The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. 

SPR was carried out by Medicilon, using the Biacore 8K equipment.

Reference